Patient data
| All patients (n=34) | Patients FEV1 <40% pred. (n=13) | |
| Age (years) | 29.9 (±7.7) | 29.5 (±7.4) |
| Male/female | 21/13 | 9/4 |
| Delta F508 mutation homozygous (%) | 53 | 40 |
| BMI before ssBACE* | 20.9 (±3.0) | 19.8 (±3.4) |
| BMI after ssBACE* | 21.2 (±3.1) | 20.6 (±3.6) |
| FEV1% pred. before ssBACE* | 45,7% (±20,1) | 26,3% (±6,5) |
| FEV1% pred. after ssBACE* | 49.1% (±20.1) | 31.5% (±10.5) |
| Time interval of FEV1% pred. before ssBACE (months)* | 6.3±4.0 | 5.2±4.4 |
| Time interval of FEV1% pred. after ssBACE (months)* | 10.3±7.0 | 9.1±7.7 |
| 1-year survival (%) | 88.2 | 84.6 |
| 5-year survival* (%) | 72.8 | 53.8 |
| Median survival after ssBACE during follow-up (months) (n=32) | 76 (0–125) | 65 (2–116) |
| 9-month non-recurrence rate (%) | 64.7 | 76.9 |
| Lung transplant 5-year observation interval* (%) | 27.3 | 53.8 |
| Time to death (months) (n=12) | 29 (0–116) | 34 (2–116) |
| Time to transplant (months) (n=11) | 34 (6–120) | 26 (6–43) |
| Insulin-dependent diabetes mellitus (%) | 17.7 | 23.1 |
| Splenomegaly with thrombopenia (%) | 11.8 | 7.7 |
| Liver cirrhosis (%) | 8.8 | 0 |
| ABPA (%) | 8.8 | 0 |
*Number of patients: n=33.
ABPA, allergic bronchopulmonary aspergillosis; BMI, body mass index; FEV1% pred., functional end-expiratory volume in 1 s in % predicted; ssBACE, super selective bronchial artery coil embolisation.